Regulus Therapeutics (RGLS) Tops Q2 EPS by 4c
Tweet
Share
E-mail
Get Alerts RGLS Hot Sheet
Join SI Premium – FREE
Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ashland (ASH) Tops Q3 EPS by 2c; offers guidance
- Finward Bancorp (FNWD) Misses Q2 EPS by 13c
- Blue Ridge Bankshares (BRBS) Reports In-Line Q2 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
